Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Author’s Reply

The Author’s Reply Am J Cancer 2003; 2 (5): 392 CORRESPONDENCE 1175-6357/03/0005-0392/$30.00/0 © Adis Data Information BV 2003. All rights reserved. tions having been considered to be the standard treatment for delayed emesis in the era before NK-1 antagonists. Such a study would be even more desirable as, given the high price of aprepitant I appreciate your comments and the given pharmacologic data at market introduction, many oncologists would tend to use it about aprepitant which indeed supports splitting a high dose on restrictively to cut treatment costs. day 1 into lower doses on days 1–3. However, it would have been Jens M. Stieler desirable if the control arms in the phase III studies consisted of Department for Hematology and Oncology, Charite Campus ´ dexamethasone plus a 5-HT3 antagonist or metoclopramide as Virchow Klinikum, Berlin, Germany prophylaxis for delayed emesis on the days 2–4; these combina- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

The Author’s Reply

Abstract

Am J Cancer 2003; 2 (5): 392 CORRESPONDENCE 1175-6357/03/0005-0392/$30.00/0 © Adis Data Information BV 2003. All rights reserved. tions having been considered to be the standard treatment for delayed emesis in the era before NK-1 antagonists. Such a study would be even more desirable as, given the high price of aprepitant I appreciate your comments and the given pharmacologic data at market introduction, many oncologists would tend to use it about aprepitant which indeed supports...
Loading next page...
 
/lp/springer-journals/the-author-s-reply-0MxVUQ2T6W
Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302050-00015
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2003; 2 (5): 392 CORRESPONDENCE 1175-6357/03/0005-0392/$30.00/0 © Adis Data Information BV 2003. All rights reserved. tions having been considered to be the standard treatment for delayed emesis in the era before NK-1 antagonists. Such a study would be even more desirable as, given the high price of aprepitant I appreciate your comments and the given pharmacologic data at market introduction, many oncologists would tend to use it about aprepitant which indeed supports splitting a high dose on restrictively to cut treatment costs. day 1 into lower doses on days 1–3. However, it would have been Jens M. Stieler desirable if the control arms in the phase III studies consisted of Department for Hematology and Oncology, Charite Campus ´ dexamethasone plus a 5-HT3 antagonist or metoclopramide as Virchow Klinikum, Berlin, Germany prophylaxis for delayed emesis on the days 2–4; these combina-

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.